Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma
-
- Hiba El Hajj
- Department of Internal Medicine,
-
- Bariaa Khalil
- Department of Biology,
-
- Botheina Ghandour
- Department of Biochemistry and Molecular Genetics, and
-
- Rihab Nasr
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon;
-
- Sharif Shahine
- Department of Biology,
-
- Akram Ghantous
- Department of Biochemistry and Molecular Genetics, and
-
- Rana Abdel-Samad
- Department of Biochemistry and Molecular Genetics, and
-
- Ansam Sinjab
- Department of Biology,
-
- Hideki Hasegawa
- Department of Pathology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan;
-
- Mark Jabbour
- Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon;
-
- William W. Hall
- Centre for Research in Infectious Diseases, School of Medicine and Medical Science, University College Dublin, Dublin 4, Ireland;
-
- Ghazi Zaatari
- Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon;
-
- Ghassan Dbaibo
- Department of Biochemistry and Molecular Genetics, and
-
- Claudio Pisano
- Biogem, Research Institute, Ariano Irpino, Italy
-
- Ali Bazarbachi
- Department of Internal Medicine,
-
- Nadine Darwiche
- Department of Biochemistry and Molecular Genetics, and
説明
<jats:title>Key Points</jats:title> <jats:p>The synthetic retinoid ST1926 induces apoptosis of ATL cells and prolongs survival of ATL mice. At the molecular level, ST1926 causes early DNA damage, upregulates p53, and downregulates Tax expression.</jats:p>
収録刊行物
-
- Blood
-
Blood 124 (13), 2072-2080, 2014-09-25
American Society of Hematology
